Eos Energy Enterprises Inc vs Edwards Lifesciences Corporation Common Stock — how do they compare? Eos Energy Enterprises Inc trades at $2.8 (market cap $1.01B), while Edwards Lifesciences Corporation Common Stock trades at $84.25 (market cap $48.56B). The key difference: Edwards Lifesciences Corporation Common Stock is far larger — about 48.1× Eos Energy Enterprises Inc's market cap, and Edwards Lifesciences Corporation Common Stock is trading nearer its 52-week high, Eos Energy Enterprises Inc nearer its low. Which is the better fit depends on your goals.
| EOSE | EW | |
|---|---|---|
Market Cap | $1.01B | $48.56B |
Volume | 39,626,541 | 6,520,488 |
Sector | Industrials | Health |
52-Week High | $19.19 | $95.18 |
52-Week Low | $2.77 | $72.65 |
Typical Hold Time | 16 Days | — |
Enterprise Value | $1.34B | $45.01B |
Signals from Pluang's Aura AI — not financial advice
Eos Energy Enterprises (EOSE) trades at $3.10, down 4.91% on the day, with a bearish technical signal from moving averages. The company is in a high-growth phase, with revenue surging from $114.20 million in 2025 to $214 million in 2026, though it remains deeply unprofitable with a net income margin of -246.76%. Recent positive developments include a major partnership with Google and a $87 million Department of Energy loan advance to expand production capacity.
The outlook is a mix of high growth potential and significant financial risk. Analyst consensus is a 'Buy' with a $7.10 price target, implying substantial upside, but the stock carries execution risk as the company burns cash to scale. Investors are betting on EOSE capturing market share in long-duration energy storage, but must tolerate volatility and ongoing losses.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Eos Energy Enterprises provides long-duration energy storage solutions. Its signature zinc-based batteries are designed for utility-scale applications, helping to stabilize power grids and integrate renewable energy.
Read more on EOSE →Edwards Lifesciences develops medical technologies for structural heart disease. Its products include transcatheter aortic-valve replacement, mitral and tricuspid therapies, and surgical structural-heart technologies.
Read more on EW →